Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.
BACKGROUND
Based on clinical representation of disease symptoms multiple sclerosis (MScl) patients can be divided into two major subtypes; relapsing remitting (RR) MScl (85-90%) and primary progressive (PP) MScl (10-15%). Proteomics analysis of cerebrospinal fluid (CSF) has detected a number of proteins that were elevated in MScl patients. Here we specifically aimed to differentiate between the PP and RR subtypes of MScl by comparing CSF proteins.


RESULTS
CSF samples (n = 31) were handled according to the same protocol for quantitative mass spectrometry measurements we reported previously. In the comparison of PP MScl versus RR MScl we observed a number of differentially abundant proteins, such as protein jagged-1 and vitamin D-binding protein. Protein jagged-1 was over three times less abundant in PP MScl compared to RR MScl. Vitamin D-binding protein was only detected in the RR MScl samples. These two proteins were validated by independent techniques (western blot and ELISA) as differentially abundant in the comparison between both MScl types.


CONCLUSIONS
The main finding of this comparative study is the observation that the proteome profiles of CSF in PP and RR MScl patients overlap to a large extent. Still, a number of differences could be observed. Protein jagged-1 is a ligand for multiple Notch receptors and involved in the mediation of Notch signaling. It is suggested in literature that the Notch pathway is involved in the remyelination of MScl lesions. Aberration of normal homeostasis of Vitamin D, of which approximately 90% is bound to vitamin D-binding protein, has been widely implicated in MScl for some years now. Vitamin D directly and indirectly regulates the differentiation, activation of CD4+ T-lymphocytes and can prevent the development of autoimmune processes, and so it may be involved in neuroprotective elements in MScl.
Stoop
Marcel P
MP
Laboratory of Neuro-Oncology, Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Singh
Vaibhav
V
Dekker
Lennard J
LJ
Titulaer
Mark K
MK
Stingl
Christoph
C
Burgers
Peter C
PC
Sillevis Smitt
Peter A E
PA
Hintzen
Rogier Q
RQ
Luider
Theo M
TM
D000328:Adult; D000595:Amino Acid Sequence; D015415:Biomarkers / Q000134:cerebrospinal fluid; D016022:Case-Control Studies; D002556:Cerebrospinal Fluid Proteins / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid* / Q000378:metabolism*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid / Q000737:chemistry; D040901:Proteomics; D012008:Recurrence
D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins; D010446:Peptide Fragments
Ann Neurol. 2009 Mar;65(3):239-48
19334069
J Proteome Res. 2009 Mar;8(3):1404-14
19159215
Proteomics. 2008 Apr;8(8):1576-85
18351689
Health Technol Assess. 2002;6(10):1-73
12022938
J Clin Endocrinol Metab. 1986 Oct;63(4):954-9
3745408
J Neurol Sci. 2010 Jan 15;288(1-2):147-50
19828154
J Clin Endocrinol Metab. 1985 Nov;61(5):969-75
3840175
Ann Neurol. 2001 Jul;50(1):121-7
11456302
J Neuroimmunol. 2001 Oct 1;119(2):327-32
11585636
J Immunol. 2009 Mar 15;182(6):3566-72
19265135
Scand J Immunol. 2008 Sep;68(3):261-9
18510590
Cell Mol Neurobiol. 2009 Mar;29(2):203-10
18807170
J Cell Biochem. 2008 Oct 1;105(2):338-43
18655192
Acta Neuropathol. 2007 Feb;113(2):195-203
17136549
PLoS One. 2007 Nov 21;2(11):e1222
18030350
Brain. 2004 Sep;127(Pt 9):1928-41
15289265
Exp Biol Med (Maywood). 2004 Dec;229(11):1136-42
15564440
Eur J Neurol. 2008 Sep;15(9):998-1001
18637954
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):611-4
15225848
Lancet. 2008 Oct 25;372(9648):1502-17
18970977
Neurosci Lett. 2009 Mar 13;452(2):214-7
19383442
J Chemother. 2001 Jun;13(3):219-34
11450879
Mult Scler. 2009 Dec;15(12):1459-65
19995843
Proteomics. 2005 Jan;5(1):290-6
15672452
Mol Cell Proteomics. 2005 Dec;4(12):2010-21
16249172
Nat Med. 2002 Oct;8(10):1115-21
12357247
Ann Neurol. 2009 Feb;65(2):151-9
19224535
Trends Biotechnol. 2004 Jul;22(7):340-5
15245906
J Neurol. 2008 Oct;255(10):1508-14
18685917
Mult Scler. 2007 Aug;13(7):840-9
17881397
Lancet Neurol. 2007 Oct;6(10):903-12
17884680
J Neuroimmunol. 2006 Oct;179(1-2):108-16
16934875
Nature. 2008 Feb 28;451(7182):1076-81
18278032
Proc Soc Exp Biol Med. 2000 Mar;223(3):230-3
10719834
Annu Rev Neurosci. 2002;25:471-90
12052917
Curr Neurol Neurosci Rep. 2007 May;7(3):239-44
17488590
J Cell Mol Med. 2009 Aug;13(8A):1586-603
19602050
J Neurosci. 2008 Oct 8;28(41):10330-8
18842892
Mult Scler. 2007 Jan;13(1):17-24
17294607
Mol Immunol. 2006 Mar;43(8):1109-15
16115686